3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE

Mix E, Ibrahim SM, Pahnke J, Glass Ä, Mazon-Pelafz I, Lemcke S, Koczan D, Gimsa U, Bansemeyer S, Scheel T, Koropka T, et al. (2006)
Journal of Autoimmunity 27(4): 251-265.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Mix, Eilhard; Ibrahim, S.M.; Pahnke, Jens; Glass, Änne; Mazon-Pelafz, I.; Lemcke, S.; Koczan, D.; Gimsa, U.; Bansemeyer, S.; Scheel, T.; Koropka, T.; Böttcher, T.
Alle
Erscheinungsjahr
2006
Zeitschriftentitel
Journal of Autoimmunity
Band
27
Ausgabe
4
Seite(n)
251-265
ISSN
0896-8411
Page URI
https://pub.uni-bielefeld.de/record/2424915

Zitieren

Mix E, Ibrahim SM, Pahnke J, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE. Journal of Autoimmunity. 2006;27(4):251-265.
Mix, E., Ibrahim, S. M., Pahnke, J., Glass, Ä., Mazon-Pelafz, I., Lemcke, S., Koczan, D., et al. (2006). 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE. Journal of Autoimmunity, 27(4), 251-265. https://doi.org/10.1016/j.jaut.2006.09.006
Mix, Eilhard, Ibrahim, S.M., Pahnke, Jens, Glass, Änne, Mazon-Pelafz, I., Lemcke, S., Koczan, D., et al. 2006. “3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE”. Journal of Autoimmunity 27 (4): 251-265.
Mix, E., Ibrahim, S. M., Pahnke, J., Glass, Ä., Mazon-Pelafz, I., Lemcke, S., Koczan, D., Gimsa, U., Bansemeyer, S., Scheel, T., et al. (2006). 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE. Journal of Autoimmunity 27, 251-265.
Mix, E., et al., 2006. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE. Journal of Autoimmunity, 27(4), p 251-265.
E. Mix, et al., “3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE”, Journal of Autoimmunity, vol. 27, 2006, pp. 251-265.
Mix, E., Ibrahim, S.M., Pahnke, J., Glass, Ä., Mazon-Pelafz, I., Lemcke, S., Koczan, D., Gimsa, U., Bansemeyer, S., Scheel, T., Koropka, T., Böttcher, T., Müller, J., Dazert, E., Antipova, V., Hoffrogge, R., Wree, A., Zschiesche, M., Strauss, U., Kundt, G., Warzok, R., Gierl, L., Rolfs, A.: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE. Journal of Autoimmunity. 27, 251-265 (2006).
Mix, Eilhard, Ibrahim, S.M., Pahnke, Jens, Glass, Änne, Mazon-Pelafz, I., Lemcke, S., Koczan, D., Gimsa, U., Bansemeyer, S., Scheel, T., Koropka, T., Böttcher, T., Müller, J., Dazert, E., Antipova, V., Hoffrogge, Raimund, Wree, A., Zschiesche, M., Strauss, U., Kundt, G., Warzok, R., Gierl, L., and Rolfs, Arndt. “3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE”. Journal of Autoimmunity 27.4 (2006): 251-265.

6 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Statins alleviate experimental nerve injury-induced neuropathic pain.
Shi XQ, Lim TK, Lee S, Zhao YQ, Zhang J., Pain 152(5), 2011
PMID: 21414721
Animal models of multiple sclerosis--potentials and limitations.
Mix E, Meyer-Rienecker H, Hartung HP, Zettl UK., Prog Neurobiol 92(3), 2010
PMID: 20558237
The mosaic of autoimmunity.
Gershwin ME., Autoimmun Rev 7(3), 2008
PMID: 18190871
One year in autoimmunity.
Selmi C., Autoimmun Rev 7(1), 2007
PMID: 17967731

55 References

Daten bereitgestellt von Europe PubMed Central.

Neuroprotection mediated by changes in the endothelial actin cytoskeleton.
Laufs U, Endres M, Stagliano N, Amin-Hanjani S, Chui DS, Yang SX, Simoncini T, Yamada M, Rabkin E, Allen PG, Huang PL, Bohm M, Schoen FJ, Moskowitz MA, Liao JK., J. Clin. Invest. 106(1), 2000
PMID: 10880044
Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin.
Stanislaus R, Pahan K, Singh AK, Singh I., Neurosci. Lett. 269(2), 1999
PMID: 10430507
Statins as immunomodulators: comparison with interferon-beta 1b in MS.
Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, Archelos JJ., Neurology 59(7), 2002
PMID: 12370451
Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin.
Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, Sallach S, Endres M, Brocke S, Nitsch R, Zipp F., J. Exp. Med. 197(6), 2003
PMID: 12629065
Atorvastatin induces T cell anergy via phosphorylation of ERK1.
Waiczies S, Prozorovski T, Infante-Duarte C, Hahner A, Aktas O, Ullrich O, Zipp F., J. Immunol. 174(9), 2005
PMID: 15843562
Statins--a cure-all for the brain?
Menge T, Hartung HP, Stuve O., Nat. Rev. Neurosci. 6(4), 2005
PMID: 15803163
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS., Nature 420(6911), 2002
PMID: 12422218
Neuroprotective effects of statins in central neurons
Simon, Restor Neurol Neurosci 20(), 2002
Therapeutic potential of lovastatin in multiple sclerosis.
Sena A, Pedrosa R, Graca Morais M., J. Neurol. 250(6), 2003
PMID: 12862032
Oral simvastatin treatment in relapsing-remitting multiple sclerosis.
Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I., Lancet 363(9421), 2004
PMID: 15145635
Structural mechanism for statin inhibition of HMG-CoA reductase.
Istvan ES, Deisenhofer J., Science 292(5519), 2001
PMID: 11349148
Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy.
Nath N, Giri S, Prasad R, Singh AK, Singh I., J. Immunol. 172(2), 2004
PMID: 14707106
Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin.
Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L., J. Exp. Med. 203(2), 2006
PMID: 16476765
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis.
Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L., Nat. Med. 8(5), 2002
PMID: 11984595
Gene-expression profiling of the early stages of MOG-induced EAE proves EAE-resistance as an active process.
Mix E, Ibrahim S, Pahnke J, Koczan D, Sina C, Bottcher T, Thiesen HJ, Rolfs A., J. Neuroimmunol. 151(1-2), 2004
PMID: 15145614
Gene-expression profiling of experimental autoimmune encephalomyelitis.
Mix E, Pahnke J, Ibrahim SM., Neurochem. Res. 27(10), 2002
PMID: 12462414
Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes.
Wandinger KP, Sturzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, McFarland HF, Martin R., Ann. Neurol. 50(3), 2001
PMID: 11558791
Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.
Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, Frank JA, Staudt L, Martin R, McFarland HF., Brain 126(Pt 6), 2003
PMID: 12764062
Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination.
Pedotti R, DeVoss JJ, Youssef S, Mitchell D, Wedemeyer J, Madanat R, Garren H, Fontoura P, Tsai M, Galli SJ, Sobel RA, Steinman L., Proc. Natl. Acad. Sci. U.S.A. 100(4), 2003
PMID: 12576552
Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin.
Paintlia AS, Paintlia MK, Singh AK, Stanislaus R, Gilg AG, Barbosa E, Singh I., J. Neurosci. Res. 77(1), 2004
PMID: 15197739
Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice.
Tuohy VK, Lu Z, Sobel RA, Laursen RA, Lees MB., J. Immunol. 142(5), 1989
PMID: 2465343
Gene expression profiling of ciliary neurotrophic factor-overexpressing rat striatal progenitor cells (ST14A) indicates improved stress response during the early stage of differentiation.
Bottcher T, Mix E, Koczan D, Bauer P, Pahnke J, Peters S, Weinelt S, Knoblich R, Strauss U, Cattaneo E, Thiesen HJ, Rolfs A., J. Neurosci. Res. 73(1), 2003
PMID: 12815707
Overexpression of glial cell line-derived neurotrophic factor induces genes regulating migration and differentiation of neuronal progenitor cells.
Pahnke J, Mix E, Knoblich R, Muller J, Zschiesche M, Schubert B, Koczan D, Bauer P, Bottcher T, Thiesen HJ, Lazarov L, Wree A, Rolfs A., Exp. Cell Res. 297(2), 2004
PMID: 15212950
A system architecture for genomic data analysis.
Glass A, Gierl L., In Silico Biol. (Gedrukt) 2(3), 2002
PMID: 12542406
gEn0M—software
Bansemer, Proc Eur Conf Comput Biol 2(), 2003
Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis.
Ibrahim SM, Mix E, Bottcher T, Koczan D, Gold R, Rolfs A, Thiesen HJ., Brain 124(Pt 10), 2001
PMID: 11571211
cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity.
Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW., Brain 126(Pt 5), 2003
PMID: 12690045
Regulation of gene expression in experimental autoimmune encephalomyelitis indicates early neuronal dysfunction.
Nicot A, Ratnakar PV, Ron Y, Chen CC, Elkabes S., Brain 126(Pt 2), 2003
PMID: 12538406
Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells.
Denoyelle C, Albanese P, Uzan G, Hong L, Vannier JP, Soria J, Soria C., Cell. Signal. 15(3), 2003
PMID: 12531431
Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19).
Spaeth N, Wyss MT, Pahnke J, Biollaz G, Trachsel E, Drandarov K, Treyer V, Weber B, Neri D, Buck A., Nucl. Med. Biol. 33(5), 2006
PMID: 16843841
Uncoupling protein 2 has protective function during experimental autoimmune encephalomyelitis.
Vogler S, Pahnke J, Rousset S, Ricquier D, Moch H, Miroux B, Ibrahim SM., Am. J. Pathol. 168(5), 2006
PMID: 16651623
The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease.
Vogelgesang S, Warzok RW, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer HK, Siegmund W, Walker LC, Pahnke J., Curr Alzheimer Res 1(2), 2004
PMID: 15975076
Targeting T cell costimulation in autoimmune disease.
Stuart RW, Racke MK., Expert Opin. Ther. Targets 6(3), 2002
PMID: 12223069
Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection.
Dedrick RL, Bodary S, Garovoy MR., Expert Opin Biol Ther 3(1), 2003
PMID: 12718733
Regional and temporal expression patterns of interleukin-10, interleukin-10 receptor and adhesion molecules in the rat spinal cord during chronic relapsing EAE.
Ledeboer A, Wierinckx A, Bol JG, Floris S, Renardel de Lavalette C, De Vries HE, van den Berg TK, Dijkstra CD, Tilders FJ, van dam AM., J. Neuroimmunol. 136(1-2), 2003
PMID: 12620647
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis.
Yilmaz A, Reiss C, Tantawi O, Weng A, Stumpf C, Raaz D, Ludwig J, Berger T, Steinkasserer A, Daniel WG, Garlichs CD., Atherosclerosis 172(1), 2004
PMID: 14709361
Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of autoimmunity.
Gran B, Hemmer B, Vergelli M, McFarland HF, Martin R., Ann. Neurol. 45(5), 1999
PMID: 10319877
Physiology and immunology of lymphatic drainage of interstitial and cerebrospinal fluid from the brain.
Knopf PM, Cserr HF, Nolan SC, Wu TY, Harling-Berg CJ., Neuropathol. Appl. Neurobiol. 21(3), 1995
PMID: 7477724
Multiple sclerosis as a generalized CNS disease--comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS.
Lindberg RL, De Groot CJ, Certa U, Ravid R, Hoffmann F, Kappos L, Leppert D., J. Neuroimmunol. 152(1-2), 2004
PMID: 15223248
Mechanisms of action of glatiramer acetate in multiple sclerosis.
Neuhaus O, Farina C, Wekerle H, Hohlfeld R., Neurology 56(6), 2001
PMID: 11288751
Gene regulation and DNA damage in the ageing human brain.
Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA., Nature 429(6994), 2004
PMID: 15190254
Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis.
Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ., J. Neuroimmunol. 152(1-2), 2004
PMID: 15223245
Development of biomarkers in multiple sclerosis.
Bielekova B, Martin R., Brain 127(Pt 7), 2004
PMID: 15180926
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 17085013
PubMed | Europe PMC

Suchen in

Google Scholar